Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Damora Therapeutics, Inc.

DMRA · Nasdaq · USD · Market cap $1.4B · 7 employees

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.

FAIL · Does not pass the screen
23.22 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price23.22 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $40.00 to $45.96, base estimate $45.00 (screen dated 2026-11-20).

Current read
Accumulation ?
Undervalued · screened 2026-11-20
  • Trend Accumulation
  • Insiders insiders bought, latest filing 2026-09-25
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price23.22 USD
Fair value45.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-10-26Read Accumulation21.71+7.0% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown22.85+1.6% to today Accumulation gives way to Markdown after a 10% rise in 13 weeks
2026-07-02Read Accumulation20.78+11.7% to today ✓First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Damora Therapeutics, Inc. holds its Accumulation at $23.22. The statistical read favours the sellers, held for 65 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateThe statistical read favours the sellers, held for 65 days
Price at the screen$23.22
Valuation13.19 trailing · -10.32 forward price to earnings
Values screenFAIL · score 70.0
Beta1.51
The Workings

Five Screens: DMRA's Results

FAIL. Accounts receivable

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.03% Below 33% Pass
Interest-bearing cash 0.00% Below 33% Pass
Receivables 99.23% Below 49% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Damora Therapeutics,'s business is fine, but its receivables are about 99% of its assets, well over the ~49% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when DMRA's ethical verdict changes

Today DMRA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 48% discount to our $45.00 fair value.

Method.

40.00Conservative45.00Base case45.96Growth case 23.22Price

USD, 2026-11-20 screen. A 48.4% under base.

The Street's Range
40.00Street low 45.00Street average 59.00Street high 23.22Price

Street: 9 covering, consensus Strong Buy. Average target +94%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-10.3x
Trailing P/E13.2xreasonably valued
EPS, trailing1.71
EPS, forward-2.19
Profit margin0.0%currently unprofitable
Return on equity-115.8%not currently earning a positive return on equity
FCF yield-1.33%
Debt to equity0.22minimal debt: a conservative balance sheet
Current ratio14.80comfortably covers its short-term bills
Beta1.51much more volatile than the market
Short interest, float0.09%
52-week range15.76 - 38.33
Market cap$1.4B
Employees7

DMRA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $22.98 +6.4% Entry 18

Since the last review it saw its composite score rise.

2026-11-16 Accumulation $21.60 -5.8% Entry 17
2026-11-05 Accumulation $22.94 +3.9% Entry 16
2026-11-04 Accumulation $22.08 +2.7% Entry 15
2026-11-03 Accumulation $21.49 +0.0% Entry 14
2026-11-02 Accumulation $21.49 +0.0% Entry 13
2026-11-01 Accumulation $21.49 -2.4% Entry 12
2026-10-31 Accumulation $22.01 +0.0% Entry 11
2026-10-30 Accumulation $22.01 +4.4% Entry 10
2026-10-29 Accumulation $21.09 -2.9% Entry 9

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on DMRA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in DMRA's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · DMRA
DateInsiderTitleTypeSharesValue
2026-09-25 Jarrett Jennifer Dir, Pres, CEO P - Purchase 12,500 $252,875

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $24.36 -18.4% · $816 -18.4%
2 months $25.82 -23.0% · $770 -23.0%
3 months $26.37 -24.7% · $754 -24.7%
6 months $29.01 -31.5% · $685 -31.5%
1 year $3.36 +491.4% · $5,914 +491.4%
2 years $13.50 +47.2% · $1,472 +47.2%
3 years $54.75 -63.7% · $363 -63.7%
5 years $140.25 -85.8% · $142 -85.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever DMRA does next, these words stay.

Damora Therapeutics, Inc. · DMRA · Accumulation · $23.22
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.